CoChat
Sign Up
Cited by 133Adrenal and Paraganglionic TumorsRenal cell carcinoma treatmentAdrenal Hormones and Disorders

Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma

Wortmann, Sebastian, Quinkler, Marcus, Ritter, Christian, Kroiss, Matthias, Johanssen, Sarah, Hahner, Stefanie, Allolio, Bruno, Fassnacht, Martin·2010·European Journal of Endocrinology
DOI 10.1530/eje-09-0804
Open this paper in CoChat — free account

Abstract

OBJECTIVE: No standard therapy for advanced adrenocortical carcinoma (ACC) is established by any randomized trial but a consensus conference 2003 recommended mitotane as monotherapy or combined with etoposide, doxorubicin and cisplatin or with streptozotocin as first-line systemic therapy. However, there is no evidence for any therapy beneficial in patients failing these therapies. Therefore, we evaluated the effects of the anti-VEGF antibody bevacizumab plus capecitabine as salvage therapy in ACC. METHODS: Patients registered with the German ACC Registry with refractory ACC progressing after cytotoxic therapies were offered treatment with bevacizumab (5 mg/kg body weight i.v. every 21 days) and oral capecitabine (950 mg/m(2) twice daily for 14 days followed by 7 days of rest) in 2006-2008. Evaluation of tumour response was performed by imaging according to response evaluation criteria in solid tumours every 12 weeks. RESULTS: Ten patients were treated with bevacizumab plus capecitabine. None of them experienced any objective response or stable disease. Two patients had to stop therapy after few weeks due to hand-foot syndrome, and three patients died on progressive disease within 12 weeks. Other adverse events were mild (grade I-II). Median survival after treatment initiation was 124 days. CONCLUSIONS: Bevacizumab plus capecitabine has no activity in patients with very advanced ACC. Hence, this regimen cannot be recommended as a salvage therapy.

Integrity signals

Registry

Crossref · 10.1530/eje-09-0804

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Overexpression of VEGFR type 2 in ACC samples was observed by immunohistochemistry.

    “In addition, overexpression of VEGFR type 2 in ACC samples was observed by immunohistochemistry (239).”

    From Adrenocortical carcinoma (2014) · cites this paper as [239]

  • An earlier clinical trial using bevacizumab proved to be ineffective.

    “However, an earlier clinical trial using bevacizumab, an anti-VEGF monoclonal antibody, proved to be ineffective (239).”

    From Adrenocortical carcinoma (2014) · cites this paper as [239]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Wortmann, S., Quinkler, M., Ritter, C., Kroiss, M., Johanssen, S., Hahner, S., Allolio, B., & Fassnacht, M.
Affiliations
University of Würzburg (DE)
Corresponding author
Fassnacht, Martin
ORCID
Venue
European Journal of Endocrinology
Publisher
Oxford University Press (OUP)
Published
2010-02
Volume
162
Issue
2
Pages
349-356
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
DOI
10.1530/eje-09-0804
OpenAlex
W2093713748
Cited by
133
References
36
Citations by year
2026: 2 · 2025: 5 · 2024: 3 · 2023: 2 · 2022: 6 · 2021: 13 · 2020: 7 · 2019: 8 · 2018: 10 · 2017: 8 · 2016: 10 · 2015: 12 · 2014: 10 · 2013: 10 · 2012: 15
FWCI
9.07
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal cell carcinoma treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
adrenocortical carcinoma, bevacizumab, capecitabine, salvage therapy, anti-VEGF therapy, refractory disease, hand-foot syndrome, treatment efficacy, survival
MeSH terms
Bevacizumab, Capecitabine, Adrenal Cortex Neoplasms, Adult, Aged, Antibodies, Monoclonal, Antimetabolites, Antineoplastic, Deoxycytidine, Drug Therapy, Combination, Female, Fluorouracil, Humans, Male, Middle Aged, Severity of Illness Index, Survival Rate, Salvage Therapy, Treatment Failure, Adrenocortical Carcinoma, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review